ABVC BioPharma (ABVC) Competitors $2.70 +0.08 (+3.05%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 08/8/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. ENGN, AVTE, IPHA, MDWD, GNFT, DMAC, EPRX, CTMX, CRBU, and ELDNShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include enGene (ENGN), Aerovate Therapeutics (AVTE), Innate Pharma (IPHA), MediWound (MDWD), GENFIT (GNFT), DiaMedica Therapeutics (DMAC), Eupraxia Pharmaceuticals (EPRX), CytomX Therapeutics (CTMX), Caribou Biosciences (CRBU), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors enGene Aerovate Therapeutics Innate Pharma MediWound GENFIT DiaMedica Therapeutics Eupraxia Pharmaceuticals CytomX Therapeutics Caribou Biosciences Eledon Pharmaceuticals enGene (NASDAQ:ENGN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations. Does the media refer more to ENGN or ABVC? In the previous week, enGene had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 6 mentions for enGene and 3 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.58 beat enGene's score of 0.39 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ENGN or ABVC? 64.2% of enGene shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 10.4% of enGene shares are owned by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ENGN or ABVC more profitable? enGene has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -32.60% -28.26% ABVC BioPharma -963.46%-29.62%-14.08% Which has higher earnings & valuation, ENGN or ABVC? ABVC BioPharma has higher revenue and earnings than enGene. ABVC BioPharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.65-2.23ABVC BioPharma$510K89.89-$4.90M-$0.13-20.77 Do analysts recommend ENGN or ABVC? enGene presently has a consensus target price of $23.29, indicating a potential upside of 532.76%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ENGN or ABVC? enGene has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. SummaryenGene and ABVC BioPharma tied by winning 8 of the 16 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.85M$2.99B$5.51B$9.72BDividend YieldN/A2.45%4.60%4.12%P/E Ratio-20.7717.2130.0324.76Price / Sales89.89319.03452.4198.43Price / CashN/A41.7736.7758.47Price / Book45.007.318.185.59Net Income-$4.90M-$54.43M$3.26B$265.99M7 Day Performance-1.82%0.01%6.13%5.07%1 Month Performance-19.40%0.63%0.07%0.61%1 Year Performance291.87%8.41%36.31%22.83% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.7897 of 5 stars$2.70+3.1%N/A+291.9%$45.85M$510K-20.7730News CoverageUpcoming EarningsENGNenGene3.2983 of 5 stars$3.94+3.1%$23.29+491.0%-44.3%$201.33MN/A-2.3931AVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.3%$199.71MN/A-2.3020News CoverageUpcoming EarningsHigh Trading VolumeIPHAInnate Pharma2.3364 of 5 stars$2.14+1.4%$11.00+414.0%-3.5%$197.27M$21.77M0.00220News CoverageMDWDMediWound1.9958 of 5 stars$17.96-2.2%$32.25+79.6%+3.2%$194.11M$19.21M-8.5980Upcoming EarningsGNFTGENFIT1.578 of 5 stars$3.88+2.3%$13.00+235.4%-4.6%$193.80M$76.77M0.00120Gap UpDMACDiaMedica Therapeutics1.734 of 5 stars$4.49+3.0%$10.75+139.4%+31.5%$192.53MN/A-7.0220High Trading VolumeEPRXEupraxia Pharmaceuticals2.7466 of 5 stars$5.35-0.5%$11.00+105.5%+96.3%$192.53MN/A-7.0429CTMXCytomX Therapeutics3.9937 of 5 stars$2.37-0.8%$5.75+142.6%+95.8%$191.07M$138.10M4.94170News CoverageGap DownCRBUCaribou Biosciences2.4363 of 5 stars$2.04-2.9%$8.50+316.7%-10.8%$189.72M$9.99M-1.26100Upcoming EarningsGap UpELDNEledon Pharmaceuticals1.6458 of 5 stars$3.13-3.7%$10.00+219.5%+3.4%$187.42MN/A-1.4910Gap UpHigh Trading Volume Related Companies and Tools Related Companies enGene Competitors Aerovate Therapeutics Competitors Innate Pharma Competitors MediWound Competitors GENFIT Competitors DiaMedica Therapeutics Competitors Eupraxia Pharmaceuticals Competitors CytomX Therapeutics Competitors Caribou Biosciences Competitors Eledon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVC Stock Alerts